|Awarded On||February 19, 2020|
|Title||Advance CT And Fluorescence Imaging Of Kidney Cancers With Glutathione-mediated Contrast Enhancements|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas at Dallas|
|Principal Investigator/Program Director||Jie Zheng|
|Cancer Sites||Kidney and Renal Pelvis|
*Pending contract negotiation
With more and more kidney cancers being diagnosed in the early stage, partial nephrectomy is becoming an increasingly important treatment for kidney cancers, in particular for those patients who have poor kidney function or cancer on both kidneys. In the current clinical settings, X-ray computerized tomography (CT) is utilized first to noninvasively localize and stage the kidney cancers, followed by fluorescently imaging normal renal parenchyma to in situ guide partial nephrectomy. However, due to the limitations of current contrast agents for X-ray CT and fluorescence imaging of kidney cancers, hundreds of clinical case studies have shown that introducing clinically approved near infrared d...